Quince Therapeutics Inc. (QNCX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Quince Therapeutics Inc.

    NASDAQ: QNCX · Real-Time Price · USD
    1.65
    0.01 (0.61%)
    At close: Oct 03, 2025, 3:59 PM
    1.68
    1.82%
    After-hours: Oct 03, 2025, 06:30 PM EDT

    Quince Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 186K 322K 175K 344K
    Gross Profit
    		 -186K -322K -175K -344K
    Operating Income
    		 -57.28M -34.62M -52.02M -90.32M
    Interest Income
    		 2.93M 3.48M 1.07M 620K
    Pretax Income
    		 -56.74M -31.58M -51.94M -89.94M
    Net Income
    		 -56.83M -31.39M -51.66M -89.94M
    Selling & General & Admin
    		 17.58M 15.39M 26.01M 29.52M
    Research & Development
    		 18.59M 9.45M 25.18M 60.8M
    Other Expenses
    		 -186K -522K -1.27M n/a
    Operating Expenses
    		 35.98M 24.32M 49.91M 90.32M
    Interest Expense
    		 n/a n/a 568K n/a
    Selling & Marketing Expenses
    		 n/a -2.3M n/a n/a
    Cost & Expenses
    		 36.17M 24.64M 50.09M 90.32M
    Income Tax Expense
    		 87K -197K -284K n/a
    Shares Outstanding (Basic)
    		 43.26M 37.24M 33.5M 29.72M
    Shares Outstanding (Diluted)
    		 43.26M 37.24M 33.5M 29.72M
    EPS (Basic)
    		 -1.31 -0.84 -1.54 -3.03
    EPS (Diluted)
    		 -1.31 -0.84 -1.54 -3.03
    EBITDA
    		 -56.55M -31.26M -49.89M -89.97M
    EBIT
    		 -56.74M -31.58M -50.09M -90.32M
    Depreciation & Amortization
    		 186K 322K 204K 344K

    Add to Watchlist